Embed Size (px)
DESCRIPTION
Renub Research has announced the addition of the "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” report to its offering Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide - Market Overview Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care. Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters. A. Hepatitis C Drugs Market & Forecast (Chapter 2) B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3) C. Hepatitis C Deals & Acquisitions (Chapter 4) D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5) E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6) F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
Citation preview
Renub Research www.renub.com
Hepatitis C Drugs – Market & Forecast
from 2010 to 2018
Source: Given in the report
Global – Forecast for Hepatitis C Drug Market (Million US$), 2013 – 2018
Renub Research www.renub.com
Order the report & get - Hepatitis C Market &
Forecast, HCV Drugs Clinical Trials, Hepatitis C
Pipeline Drugs Sales & Forecast - Worldwide
A comprehensive 164 page report,
supported by data-rich 25 Figures and 2
Tables
Renub Research www.renub.com
Data Available for –Pegasys, Pegintron, Incivek,
Victrelis Sales & Forecast from 2005 to 2018
Source: Given in the report
Global – Pegasys Sales (Million US$), 2005 – 2012
Renub Research www.renub.com
The Following Pipeline Drugs Clinical Trials (Drugs in Phase III) covered in the report
• Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
• Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
• Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
• Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
• Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
• BI-207127 (Company: Boerhinger Ingelheim)
• ABT-267 (Company: Abbott Laboratories)
• ABT-072/333 (Company: Abbott Laboratories)
• Alisporivir (Company: Novartis)
Renub Research www.renub.com
The Following Pipeline Drugs Clinical Trials (Drugs in Phase II) covered in the report
• Mericitabine (RG-7128) (Company: Roche)
• Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
• GS-9256 (Company: Gilead Sciences)
• MK-5172 (Company: Merck)
• Sovaprevir (ACH-1625) (Company: Achillion)
• IDX-320 (Company: Idenix)
• MK-8742 (Company: Merck)
• IDX-719 (Company: Idenix)
• Setrobuvir (ANA-598) (Company: Roche)
• GS-9669 (Company: Gilead Sciences )
• GS-9190 (Tegobuvir) (Company: Gilead Sciences)
• BMS-791325 (Company: Bristol-Myers Squibb)
Renub Research www.renub.com
The following pipeline drugs sales covered in the report :
Simeprevir (TMC 435), Faldaprevir (BI 201335), Asunaprevir (BMS-
650032), Sofosbuvir (PSI-7977 or GS-7977) from 2014 to 2018
Source: Given in the report
Global – Forecast for Simeprevir (TMC 435) Sales (Million US$), 2014 – 2018
Renub Research www.renub.com
The following pipeline drugs sales covered in the report :
Daclatasvir (BMS-790052), ABT-450/r (Ritonavir), ABT-
072/333, Alisporivir, Danoprevir (RG7227), GS-9256, VX-222
from 2014 to 2018
Source: Given in the report
Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US$), 2014 – 2018
Renub Research www.renub.com
Order Form Scan and e-mail this page to [email protected], alternatively one
can also write the Contact Information in an e-mail and mail it.
Else you can also fax this form to +91-120-424-9780
Questions? Please call
+1-678-302-0700 (USA)
+91-120-421-9822 (India), ,+91-120-424-9780
or mail to [email protected]
Renub Research www.renub.com
Format
Report Title: Hepatitis C Market & Forecast, HCV Drugs Clinical
Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide For More Details:
http://www.renub.com/report/hepatitis-c-market-forecast-hcv-
drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast---
worldwide-118
Single User
(Email from
Publisher)
Hard Copy
(Mail Delivery)
CD – Rom
(Mail Delivery)
Global Site License
(Multiple User
License)
US$ 1,290 US$ 1,440 US$ 1,390 US$ 2,090
Renub Research www.renub.com
For ordering this report: Three easy ways to
place your order
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/buyreport/118-1454
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=118&pid=1454
To pay by Wire Transfer, please, fill in your contact details in the
form below:
Renub Research www.renub.com
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Renub Research www.renub.com
Contact Information
First Name: Last Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message:
Renub Research www.renub.com
Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st Floor,
C-86, Sector-10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
[email protected] or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
![Impact of hepatitis C status on 20-year mortality of ...Hepatitis C has been recognized as the major cause of chronic hepatitis in people who inject drugs since 1992 [1]. Epidemiologic](https://img.dokumen.tips/doc/110x75/5f69bf36de7cfb0942791081/impact-of-hepatitis-c-status-on-20-year-mortality-of-hepatitis-c-has-been-recognized.jpg)
